Biogen Appoints Jane Grogan as Head of Research
Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane
Grogan, Ph.D., as Executive Vice President, Head of Research
effective 2 October 2023. Dr. Grogan will be a member of Biogen’s
Executive Committee reporting to Christopher A. Viehbacher,
President and Chief Executive Officer.
“Dr. Grogan is a pioneering scientist whose groundbreaking
discoveries at Genentech helped pave the way for development of
targeted autoimmune and oncology therapies. I believe Jane will be
a strong asset to Biogen as we seek to bring a greater number of
innovative medicines to market faster and more effectively,” said
Mr. Viehbacher. “Together with Dr. Priya Singhal, EVP and Head of
Development, she will determine the company’s portfolio strategy
with the aim of creating value and making decisions aligned with
our scientific expertise and translational capabilities.”
Jane Grogan brings nearly two decades of experience leading
biotech research, including fifteen years with Genentech. Dr.
Grogan most recently served as the Chief Scientific Officer at
Graphite Bio, a cell and gene editing company. Prior to this, she
served as Chief Scientific Officer at ArsenalBio, a privately held
programmable T cell therapy company, responsible for research,
discovery and preclinical pipeline, including development for the
company’s first product candidate.
During her time at Genentech, Dr. Grogan served in a number of
increasingly senior roles across Immunology and Immuno-oncology,
covering research strategies and drug development across RA, Lupus,
MS, IBD and Cancer. As Head of Adaptive Tumor Immunity and
Principal Scientist in Cancer Immunology Discovery Research at
Genentech, Dr. Grogan’s research primarily delved into mechanisms
of T cell activation, tolerance-induction, and epigenetic
modifiers, adopting an integrative methodology combining
bioinformatics, biology, and diagnostics. Her laboratory identified
crucial regulators of both effector and regulatory T cells and
progressed several targets into clinical trials for autoimmune and
oncology indications, such as anti-lymphotoxin alpha for rheumatoid
arthritis and anti-TIGIT for cancer immunotherapy. At Genentech,
Dr. Grogan also integrated strategy between Early Discovery
Research, Clinical Development, and Business Development and was
project leader for engineered T cell therapies.
During her career, Dr. Grogan has published more than 60 papers
in a wide array of journals and is listed as inventor on more than
20 patents. She received her Bachelor of Science at the University
of Melbourne, Australia, earned her PhD in Immunology from Leiden
University, The Netherlands, and underwent post-doctoral training
as an Alexander von Humboldt Fellow at the DRFZ in Berlin and as a
Howard Hughes Fellow at the University of California, San
Francisco.
About BiogenFounded in 1978, Biogen is a
leading global biotechnology company that has pioneered multiple
breakthrough innovations including a broad portfolio of medicines
to treat multiple sclerosis, the first approved treatment for
spinal muscular atrophy, and two co-developed treatments to address
a defining pathology of Alzheimer’s disease. Biogen is advancing a
pipeline of potential novel therapies across neurology,
neuropsychiatry, specialized immunology and rare diseases and
remains acutely focused on its purpose of serving humanity through
science while advancing a healthier, more sustainable and equitable
world.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social
media - X, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor This news release
contains forward-looking statements, including statements relating
to our business activities; our strategy and plans and the
potential of our commercial business and pipeline programs; capital
allocation and investment strategy. These forward-looking
statements may be accompanied by such words as “anticipate,”
“believe,” “could,” “estimate,” “expect,” “forecast,” “intend,”
“may,” “plan,” “potential,” “project,” “target,” “will” and other
words and terms of similar meaning. You should not place undue
reliance on these statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including: our dependence on sales from our
products; uncertainty of long-term success in developing,
licensing, or acquiring other product candidates or additional
indications for existing products; failure to compete effectively
due to significant product competition in the markets for our
products; failure to successfully execute or realize the
anticipated benefits of our strategic and growth initiatives;
difficulties in obtaining and maintaining adequate coverage,
pricing, and reimbursement for our products; our dependence on
collaborators, joint venture partners, and other third parties for
the development, regulatory approval, and commercialization of
products and other aspects of our business, which are outside of
our full control; the potential impact of the conflict in Ukraine;
risks associated with current and potential future healthcare
reforms; risks related to commercialization of biosimilars; risks
relating to the distribution and sale by third parties of
counterfeit or unfit versions of our products; risks relating to
the use of social media for our business; failure to obtain,
protect, and enforce our data, intellectual property, and other
proprietary rights and the risks and uncertainties relating to
intellectual property claims and challenges; the risk that positive
results in a clinical trial may not be replicated in subsequent or
confirmatory trials or success in early stage clinical trials may
not be predictive of results in later stage or large scale clinical
trials or trials in other potential indications; risks associated
with clinical trials, including our ability to adequately manage
clinical activities, unexpected concerns that may arise from
additional data or analysis obtained during clinical trials,
regulatory authorities may require additional information or
further studies, or may fail to approve or may delay approval of
our drug candidates; the occurrence of adverse safety events,
restrictions on use with our products, or product liability claims;
risks relating to technology failures or breaches; problems with
our manufacturing processes; risks relating to management and
personnel changes, including attracting and retaining personnel;
failure to comply with legal and regulatory requirements; the risks
of doing business internationally, including currency exchange rate
fluctuations; risks relating to investment in our manufacturing
capacity; the direct and indirect impacts of the ongoing COVID-19
pandemic on our business, results of operations, and financial
condition; fluctuations in our operating results; risks related to
investment in properties; the market, interest, and credit risks
associated with our investment portfolio; risks relating to share
repurchase programs; risks relating to access to capital and credit
markets; risks related to indebtedness; change in control
provisions in certain of our collaboration agreements; fluctuations
in our effective tax rate; environmental risks; and any other risks
and uncertainties that are described in other reports we have filed
with the U.S. Securities and Exchange Commission.
This news release speaks only as of the date of this press
release. We do not undertake any obligation to publicly update any
forward-looking statements.
MEDIA CONTACT:BiogenJack Cox+ 1 781 464
3260public.affairs@biogen.com |
INVESTOR CONTACT:BiogenChuck Triano+1 781 464
2442IR@biogen.com |
Biogen (LSE:0R1B)
Historical Stock Chart
From Apr 2024 to May 2024
Biogen (LSE:0R1B)
Historical Stock Chart
From May 2023 to May 2024